Stopping acid pills in liver cirrhosis: test placebo effect
Treatments studied
Part of Digestive system clinical trials.
This study tests whether stopping proton-pump inhibitor (PPI) acid-reducing medication is safe and works as expected for people with liver cirrhosis. Participants switch to either the study medication or a placebo (inactive pill) under close monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cirrhosis
- You were hospitalized recently, or during the last 0 to 42 days, for complications of cirrhosis
- You have taken a proton-pump inhibitor (PPI) for at least 28 days before screening
- Your PPI dose is no more than one standard dose per day for at least 7 days before screening
- You can understand the study and sign consent, and you can stay available for the full study
- If you can become pregnant, you must not be pregnant or breastfeeding, and you must use required birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a heartburn medication (pantoprazole) helps patients with liver cirrhosis who have had a procedure to treat enlarged veins in the esophagus or stomach. It looks at how well the medicine works when given after this procedure to prevent complications.
This trial tests whether taking low-dose aspirin can help prevent liver cancer in people with cirrhosis (scarring of the liver). Cirrhosis makes the liver more likely to develop cancer, and aspirin might reduce that risk.
This study tests whether it is safe to stop taking acid-reducing pills (PPIs) for people with inactive IBD. If you have been on a PPI for over 6 months and your IBD is stable, you may be able to join.
This study tests whether taking a proton pump inhibitor (a medicine that lowers stomach acid) helps people with liver cirrhosis who have sudden bleeding from enlarged esophagus veins (varices). It may help reduce bleeding and complications by changing stomach/upper digestive tract conditions during this urgent time.
This trial tests whether proton pump inhibitors (PPIs) can help people with cirrhosis who are hospitalized for variceal bleeding. It looks at whether PPIs reduce complications during the hospital stay.
This study tests whether it is safe and helpful to reduce or stop daily high-dose heartburn medications (called PPIs) in patients who might not need them anymore. It is for adults who take a strong PPI every day and can communicate in German.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.